Every material Form 8-K Aprea Therapeutics, Inc. has filed with the SEC since August 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Aprea Therapeutics reported a third-quarter 2026 net loss of $4.8 million, or $(0.09) per share, up from $3.0 million, or $(0.47) per share, a year earlier, as research and development spending rose. The company had $37.8 million in cash and cash equivalents at September 30, 2026, and expects that cash to fund operations into the first quarter of 2028, while it expands its Phase 1 trial of APR-1051.
Q3 2026 operating loss was $5.2 million, compared with $3.1 million in Q3 2025; no grant revenue was recorded versus $1,848 a year earlier.
R&D expenses were $3.3 million, up from $1.6 million, mainly due to a $2.1 million increase for the ACESOT-1051 trial.
Cash and cash equivalents were $37.8 million at September 30, 2026, up from $14.6 million at December 31, 2025.
Interim ACESOT-1051 data will be presented as an oral presentation on November 20, 2026, at the ENA 2026 symposium in Barcelona.
Aprea Therapeutics announced an update to its intellectual property portfolio covering its precision oncology programs, citing 28 issued and 30 pending patents. The filing reports no financial results, and it does not describe any change in the company's clinical programs or financial position.
Company reports 28 issued and 30 pending patents across its programs.
WEE1 family of applications, if granted, would expire in 2047, excluding any regulatory exclusivities.
ATR inhibitor granted patents expire 2035-2037; pending applications could extend exclusivity into 2045.
Company is considering further development of ATRN-119 in combination therapies after completing dose escalation.
Aprea Therapeutics reported results for the quarter ended June 30, 2026, showing a net loss of $3.6 million, up from $3.2 million a year earlier, and no grant revenue compared with $118,111 in the second quarter of 2025. The company said its cash can fund projected operations into the first quarter of 2028 and that it is expanding enrollment in its APR-1051 Phase 1 trial, with the next clinical data update expected in the fourth quarter of 2026.
Net loss was $3.6 million, or $(0.07) per basic share, on about 53.5 million weighted-average shares, versus $3.2 million, or $(0.53) per share, on about 6.1 million shares in Q2 2025.
Operating loss was $4.0 million, compared with $3.4 million in the second quarter of 2025; grant revenue was zero versus $118,111 a year earlier.
Cash and cash equivalents were $41.2 million as of June 30, 2026, up from $14.6 million on December 31, 2025, which the company said funds operations into the first quarter of 2028.
The company plans to enroll at least 50 patients in uterine serous carcinoma or cyclin E-overexpressing platinum-resistant ovarian cancer, with dose escalation and backfill completion expected in Q2 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Aprea Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →